Dissecting the OTC-Ornithine-ZBTB7A Pathway in Realgar-Induced CNS Toxicity

Study Background and Research Question

Realgar, a mineral-based traditional Chinese medicine rich in arsenic, has been used for centuries in East Asian clinical practice, yet concerns persist regarding its safety, especially with chronic or excessive dosing. Recent reports of arsenic-associated neurotoxicity have highlighted the need to clarify the molecular mechanisms linking hepatic metabolism to central nervous system (CNS) injury. This research specifically addresses how realgar-derived arsenic impacts the liver–brain axis, focusing on the interplay between hepatic ornithine transcarbamylase (OTC) activity, L-Ornithine accumulation, and astrocyte metabolic dysfunction. The central question is: how does disruption of the urea cycle by realgar potentiate CNS toxicity through metabolic and transcriptional pathways in astrocytes?

Key Innovation from the Reference Study

The reference study (Ye et al., 2025) provides a mechanistic framework connecting hepatic dysfunction to CNS outcomes in the context of arsenic exposure. The authors identify the OTC-Ornithine-ZBTB7A axis as a critical mediator of neurotoxicity, demonstrating that realgar-induced inhibition of hepatic OTC causes systemic and cerebral accumulation of L-Ornithine. This non-proteinogenic amino acid, acting as a urea cycle intermediate, directly modulates the transcriptional regulator ZBTB7A in astrocytes, leading to repression of key glycolytic enzymes. This finding bridges hepatic nitrogen disposal pathways and brain energy metabolism, introducing a new paradigm for understanding metabolic crosstalk in toxin-induced neurological disorders.

Methods and Experimental Design Insights

To interrogate this metabolic network, the researchers employed a combination of in vivo and in vitro models. Animal studies utilized conditional intervention designs, including Zbtb7aGfABC1D KD (astrocyte-specific knockdown) and OtcTBG OE (liver-specific OTC overexpression) mouse models, both subjected to realgar exposure. Additional pharmacological intervention with chrysophanol was included to probe potential protective effects. For cellular analyses, the C8-D1A mouse astrocyte cell line was transfected with si-Zbtb7a and exposed to inorganic arsenic (iAs3+) and L-Ornithine. The study leveraged single-cell transcriptomics, metabolomics, neurobehavioral assays, molecular biology techniques, and histopathological evaluation to dissect pathway activity and phenotypic outcomes. Molecular docking was used to confirm specific binding between L-Ornithine and ZBTB7A, supporting the hypothesized regulatory mechanism.

Protocol Parameters

• Animal model intervention: Use Zbtb7aGfABC1D KD and OtcTBG OE mice to dissect astrocyte- and liver-specific effects of realgar exposure, with or without chrysophanol co-administration.
• Realgar exposure: Administer realgar at clinically relevant doses, monitoring for signs of CNS dysfunction and hepatic injury.
• Astrocyte cell line experiments: Transfect C8-D1A cells with si-Zbtb7a and treat with iAs3+ (inorganic arsenic) plus L-Ornithine to assess gene expression and glycolytic function.
• Metabolomic profiling: Quantify L-Ornithine and related urea cycle intermediates in serum and brain tissue to establish metabolite fluxes.
• Neurobehavioral assessments: Evaluate learning, memory, and anxiety-like behavior in treated mice using standardized behavioral tests.
• Molecular docking: Use computational approaches to assess binding affinity between (S)-2,5-diaminopentanoic acid and ZBTB7A protein.

Core Findings and Why They Matter

Central to the study's findings is the demonstration that arsenic from realgar not only crosses the blood–brain barrier but also accumulates in the frontal cortex, where it suppresses glycolysis in astrocytes. Mechanistically, arsenic-induced upregulation of ZBTB7A represses glycolytic genes (Aldoa, Ldha, Pgam1), reducing lactate availability and precipitating an energy deficit in neurons. This chain of events results in increased apoptosis, oxidative stress, and observable deficits in cognition and exploratory behavior, as detailed in the reference study. Importantly, hepatic OTC inhibition by arsenic impairs the urea cycle, causing systemic and brain-specific accumulation of L-Ornithine. Molecular docking and functional assays reveal that this surplus L-Ornithine modulates ZBTB7A activity in astrocytes, amplifying metabolic suppression and CNS toxicity. The protective effect of chrysophanol, which preserves both hepatic OTC function and astrocyte glycolytic activity, further validates the centrality of the OTC-Ornithine-ZBTB7A axis in mediating these pathologies.

Comparison with Existing Internal Articles

Several recent analyses have contextualized these findings within broader research on metabolic and CNS toxicity. For example, OTC-Ornithine-ZBTB7A Axis in Realgar-Induced CNS Toxicity synthesizes similar mechanistic insights, emphasizing the importance of hepatic–central metabolic coupling in neurotoxicity. Likewise, L-Ornithine as a Translational Lever explores the value of L-Ornithine as a research tool for dissecting nitrogen metabolism and its neurological sequelae, connecting product deployment strategies to recent mechanistic advances. These internal resources highlight the translational potential of targeting the OTC-Ornithine-ZBTB7A pathway for both basic and applied biomedical research, aligning with the reference study’s implications for experimental model design and biomarker identification.

Limitations and Transferability

Despite its comprehensive approach, the study has several limitations. The conditional genetic interventions in mice, while powerful, may not fully recapitulate the complexity of human hepatic and neural responses to chronic arsenic exposure. Additionally, while the single-cell transcriptomic and metabolomic data offer granular insights, the cross-species applicability of these molecular signatures requires further validation. The role of L-Ornithine and ZBTB7A in other neurotoxic contexts remains to be elucidated, as does the impact of additional urea cycle intermediates or environmental cofactors. The study’s findings are most directly applicable to models of toxin-induced CNS dysfunction with a clear hepatic metabolic component; extrapolation to unrelated neurological disorders should be undertaken with caution.

Research Support Resources

For researchers seeking to model urea cycle disruption, ammonia detoxification pathways, or metabolic enzyme assays in vitro or in vivo, L-Ornithine ((S)-2,5-diaminopentanoic acid) is a critical tool. High-purity L-Ornithine (SKU B8919) is available from APExBIO for biochemical and metabolic research applications, with validated solubility and quality parameters to support reproducibility. Further integration of this reagent into cell-based or animal model workflows can facilitate detailed probing of the metabolic mechanisms highlighted in the reference study.